Search | Clinical Trials Finder

Conditions: Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
Interventions: brentuximab vedotin, rituximab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more

Conditions: Advanced Solid Tumors
Interventions: LCB84, Anti-PD-1 monoclonal antibody; Drug
Lead sponsor: LigaChem Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Food Allergy
Interventions: Omalizumab, Food Flour Buildup; Drug
Lead sponsor: Kari Christine Nadeau; Other
Eligibility: 4 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more

Conditions: Clostridium Difficile Colitis
Interventions: CRS3123, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Smoking, Nicotine Addiction, Surgery
Interventions: ENDD (NJOY), NRT (NicoDerm CQ), telephone counseling, brief advice, brochure; Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions: AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 17
States / cities: Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more

Conditions: HIV, Drug Use
Interventions: Y2Prevent; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 18 Years to 24 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Drug Drug Interaction
Interventions: EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Interventions: GB-4362, enfortumab vedotin (EV), Pembrolizumab; Drug
Lead sponsor: Generate Biomedicines; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Duarte, California • Irvine, California • Orlando, Florida + 7 more

Conditions: Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
Interventions: Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Eribulin, Fluorouracil, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Nivolumab, Olaparib, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Selinexor, Topotecan; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Pancreatic Neoplasms
Interventions: Vitamin E δ-Tocotrienol; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pain, Sleep Disturbance, Anxiety
Interventions: Commercially available, orally ingestible CBD product; Other
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Healthy Volunteers
Interventions: Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
Interventions: Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Nicotine Dependence
Interventions: Juul Electronic cigarette, Very Low Nicotine Cigarettes, Active Nicotine Patch, Placebo Patch; Device · Other · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years and older
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Contraception
Interventions: Misoprostol, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Interventions: KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses, Cyclophosphamide 500 mg/m2; 2 doses, Fludarabine 30mg/m2 3 doses, Cyclophosphamide 500 mg/m2; 3 doses, Fludarabine 25mg/m2 3 days, Cyclophosphamide 250 mg/m2; 3 days, Tecartus, Abecma, Intravenous Suspension, Cyclophosphamide 900 mg/m2; 1 day, Breyanzi Injectable Product; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Asthma, Obesity
Interventions: CXA-10, Matching Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Smoking, Tobacco Use
Interventions: Product A, Product B, Product C, Product D, Product E, Product F, Product G, Product N; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lexington, Kentucky • Knoxville, Tennessee

Conditions: Polysubstance Drug Use (Indiscriminate Drug Use)
Interventions: Contingency Management for Emerging Adults (CM-EA), Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services; Behavioral
Lead sponsor: Chestnut Health Systems; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Hiram, Georgia • Bloomington, Illinois • Granite City, Illinois + 5 more

Conditions: Healthy Participants
Interventions: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Healthy, Non-Drug- Dependent, Recreational Opioid Users
Interventions: Placebo, Oxycodone 20mg, gabapentin 600 mg, Gabapentin 1200mg, Gabapentin 600 mg + Oxycodone 20 mg, Gabapentin 1200 mg + Oxycodone 20 mg; Drug
Lead sponsor: Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Vascular Anomalies
Interventions: Marimastat; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza, SARS-CoV-2
Interventions: mRNA-1083; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 932 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Hialeah, Florida • Hollywood, Florida • Miami, Florida + 9 more

Search by objective public record fields.

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Multi Immunotherapy to Test Tolerance and Xolair

Phase I Trial of a Single Dose of CRS3123

The END Perioperative Smoking Pilot Study

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia

Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use

Intra Uterine Device Insertion in Nulliparous Women

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

Modern Nicotine Oral Product Abuse Liability

Leveraging Parents and Peers to Increase Recovery Capital in Emerging Adults

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users

Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)